Related Experiment Video For Biliary tract cancer
Updated: Apr 14, 2026

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma
Published on: February 13, 2026
Effect of Case Discussion with Expert Centers on Treatment Outcome of Intrahepatic Cholangiocarcinoma
Thomas C Zwaan1, Stefan Buettner1, Lydia G van der Geest2
1Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Background:
Intrahepatic cholangiocarcinoma (iCCA) is a rare liver malignancy with poor prognosis. This study assessed how case discussion of patients at expert centers within multidisciplinary team meetings (MDTs) is associated with treatment and survival in iCCA patients in the Netherlands.
Methods:
This retrospective cohort study analyzed data registered in the Netherlands Cancer Registry between 2017 and 2021 on all consecutive patients diagnosed with iCCA. Data included patient demographics, tumor characteristics, and the involvement of a member of an expert center at case discussions. Outcomes included overall survival and treatment type, which was specified as tumor-directed (e.g., resection, ablation, systemic treatment, or other treatment modalities) vs. supportive care only.
Results:
Among the 1.622 patients included, median overall survival was 5.4 months, and 825 (50.9%) underwent tumor-directed therapy. Patients discussed at expert centers (59.6%) were more likely to receive tumor-directed therapy (58.8% vs. 37.2%, P < 0.001) and undergo surgery (20.3% vs. 5.7%, P < 0.001). In the multivariable analysis, patients discussed at expert centers had better overall survival (hazard ratio 0.69 (0.62-0.78)).
Conclusions:
Centralized care through MDT discussion at expert centers was associated with increased likelihood of receiving tumor-directed therapy and improved survival in iCCA patients. This study highlights the potential for improved patient outcomes through structured expert consultations.
Related Concept Videos
Treatment Resistant Cancers
Chronic Pancreatitis II: Collaborative Care
Assessment:

